A phase I trial of divarasib, a next-generation KRASG12C inhibitor under study to treat solid tumors, establishes the agent as safe and highlights its improved efficacy when compared with other drugs in its class. Large, randomized trials of the drug as a monotherapy and in combination with other therapies are needed to confirm these results and determine how best to use divarasib in patients with solid tumors.

You do not currently have access to this content.